Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| gabapentin, sulfasalazine, memantine, temozolomide, radiotherapy | NFKB2 | Direct | 1 | ||||||||
| sulfasalazine | NFKB2 | Direct | 1 | ||||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | ABL1 | SSL via ABL1 | 4 | ||||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | ABL1 | SSL via ABL1 | 4 | ||||||||
| 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis | PDPK1 | SSL via PDPK1 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | ABL1 | SSL via ABL1 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | EPHB4 | SSL via EPHB4 | 3 | ||||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | ABL1 | SSL via ABL1 | 2 | ||||||||
| alendronate, etidronate, ibandronate, risedronate, raloxifene | ESR2 | SSL via ESR2 | 2 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | ABL1 | SSL via ABL1 | 2 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | EPHB4 | SSL via EPHB4 | 2 | ||||||||
| bryostatin 1, paclitaxel | CASP8 | SSL via CASP8 | 2 | ||||||||
| carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy | PDPK1 | SSL via PDPK1 | 2 | ||||||||
| cpt- 11, cisplatin, celecoxib, radiation, surgery | PDPK1 | SSL via PDPK1 | 2 | ||||||||
| entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib | JAK2 | SSL via JAK2 | 2 | ||||||||
| ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib | JAK2 | SSL via JAK2 | 2 | ||||||||
| regorafenib | ABL1 | SSL via ABL1 | yes | 2 | |||||||
| regorafenib, laboratory biomarker analysis | ABL1 | SSL via ABL1 | 2 | ||||||||
| 7-hydroxystaurosporine, fluorouracil | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| 7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study, laboratory biomarker analysis | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | ABL1 | SSL via ABL1 | 1 | ||||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | EPHB4 | SSL via EPHB4 | 1 | ||||||||
| aldesleukin, antibody therapy, fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, laboratory biomarker analysis, leucovorin calcium, oxaliplatin, paclitaxel albumin-stabilized nanoparticle formulation, sargramostim | IL2RB | SSL via IL2RB | 1 | ||||||||
| aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation | IL2RB | SSL via IL2RB | 1 | ||||||||
| aldesleukin, autologous tumor cell vaccine, muromonab-cd3, sargramostim, therapeutic autologous lymphocytes, surgical procedure, radiation therapy | IL2RB | SSL via IL2RB | 1 | ||||||||
| aldesleukin, biopsy, biospecimen collection, computed tomography, cyclophosphamide, excisional biopsy, fludarabine, magnetic resonance imaging, standard treatment, therapeutic tumor infiltrating lymphocytes | IL2RB | SSL via IL2RB | 1 | ||||||||
| aldesleukin, muromonab-cd3, therapeutic tumor infiltrating lymphocytes, conventional surgery | IL2RB | SSL via IL2RB | 1 | ||||||||
| aldesleukin, therapeutic autologous lymphocytes, adjuvant therapy, conventional surgery | IL2RB | SSL via IL2RB | 1 | ||||||||
| aldesleukin, therapeutic autologous lymphocytes, zoledronic acid | IL2RB | SSL via IL2RB | 1 | ||||||||
| au-007, aldesleukin, avelumab | IL2RB | SSL via IL2RB | 1 | ||||||||
| azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab | DNMT1 | SSL via DNMT1 | 1 | ||||||||
| bethanechol | CHRM5 | SSL via CHRM5 | 1 | ||||||||
| bethanechol, gemcitabine, nab-paclitaxel | CHRM5 | SSL via CHRM5 | 1 | ||||||||
| bevacizumab, dasatinib, placebo | ABL1 | SSL via ABL1 | 1 | ||||||||
| bevacizumab, dasatinib, placebo | EPHB4 | SSL via EPHB4 | 1 | ||||||||
| bosutinib | ABL1 | SSL via ABL1 | yes | 1 | |||||||
| botensilimab, balstilimab, chloroquine phosphate, celecoxib | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| carboplatin, 3 dimensional conformal radiation therapy, propranolol, intensity modulated radiation therapy, paclitaxel | ADRB3 | SSL via ADRB3 | 1 | ||||||||
| celecoxib, cyclophosphamide, etoposide, thalidomide | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| celecoxib, isotretinoin, temozolomide, thalidomide | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| celecoxib, temozolomide, thalidomide, adjuvant therapy | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| chemotherapy, cladribine, radiation therapy | PNP | SSL via PNP | 1 | ||||||||
| chemotherapy, suramin | F2 | SSL via F2 | 1 | ||||||||
| chlorpromazine, temozolomide, radiation therapy | ADRA1A | SSL via ADRA1A | 1 | ||||||||
| cyclophosphamide, fludarabine, aldesleukin, anti-hcd70 car transduced pbl | IL2RB | SSL via IL2RB | 1 | ||||||||
| dabigatran etexilate, warfarin | F2 | SSL via F2 | 1 | ||||||||
| dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride | ABL1 | SSL via ABL1 | 1 | ||||||||
| dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride | EPHB4 | SSL via EPHB4 | 1 | ||||||||
| dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method | ABL1 | SSL via ABL1 | 1 | ||||||||
| dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method | EPHB4 | SSL via EPHB4 | 1 | ||||||||
| dasatinib, laboratory biomarker analysis, physiologic testing | ABL1 | SSL via ABL1 | 1 | ||||||||
| dasatinib, laboratory biomarker analysis, physiologic testing | EPHB4 | SSL via EPHB4 | 1 | ||||||||
| dasatinib, mfolfox6 | ABL1 | SSL via ABL1 | 1 | ||||||||
| dasatinib, mfolfox6 | EPHB4 | SSL via EPHB4 | 1 | ||||||||
| dasatinib, pharmacological study | ABL1 | SSL via ABL1 | 1 | ||||||||
| dasatinib, pharmacological study | EPHB4 | SSL via EPHB4 | 1 | ||||||||
| dasatinib, temozolomide, placebo, radiation therapy | ABL1 | SSL via ABL1 | 1 | ||||||||
| dasatinib, temozolomide, placebo, radiation therapy | EPHB4 | SSL via EPHB4 | 1 | ||||||||
| decitabine, gemcitabine | DNMT1 | SSL via DNMT1 | 1 | ||||||||
| desflurane | KCNA1 | SSL via KCNA1 | 1 | ||||||||
| dexamethasone, ondansetron, quality-of-life assessment | HTR4 | SSL via HTR4 | 1 | ||||||||
| dipyridamole, fluorouracil, leucovorin calcium, mitomycin c | PDE10A | SSL via PDE10A | 1 | ||||||||
| dipyridamole, fluorouracil, leucovorin calcium, mitomycin c | PDE5A | SSL via PDE5A | 1 | ||||||||
| disulfiram, copper, alkylating agents | APOC3 | SSL via APOC3 | 1 | ||||||||
| disulfiram, copper, alkylating agents | F2 | SSL via F2 | 1 | ||||||||
| disulfiram, copper, alkylating agents | HSP90B1 | SSL via HSP90B1 | 1 | ||||||||
| disulfiram, copper, alkylating agents | SERPIND1 | SSL via SERPIND1 | 1 | ||||||||
| durvalumab, gemcitabine, nab paclitaxel, tremelimumab, propranolol, cisplatin | ADRB3 | SSL via ADRB3 | 1 | ||||||||
| e. coli cd-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium, pharmacological study, laboratory biomarker analysis | DNMT1 | SSL via DNMT1 | 1 | ||||||||
| e7 tcr cells, aldesleukin, fludarabine, cyclophosphamide | IL2RB | SSL via IL2RB | 1 | ||||||||
| endoscopic variceal ligation, carvedilol | ADRA1A | SSL via ADRA1A | 1 | ||||||||
| entrectinib | JAK2 | SSL via JAK2 | yes | 1 | |||||||
| epidermal growth factor receptor(egfrv)iii chimeric antigen receptor (car) transduced pbl, aldesleukin, fludarabine, cyclophosphamide | IL2RB | SSL via IL2RB | 1 | ||||||||
| eras-007, encorafenib, cetuximab, palbociclib | MAPK9 | SSL via MAPK9 | 1 | ||||||||
| eras-007, encorafenib, cetuximab, palbociclib | STK36 | SSL via STK36 | 1 | ||||||||
| ethanol, enoxaparin | F2 | SSL via F2 | 1 | ||||||||
| flucytosine, polymerase chain reaction, immunohistochemistry staining method, gene therapy, pharmacological study, 3-tesla magnetic resonance imaging, laboratory biomarker analysis, therapeutic conventional surgery, e. coli cd-expressing genetically modified neural stem cells | DNMT1 | SSL via DNMT1 | 1 | ||||||||
| ft-2102, azacitidine, nivolumab, gemcitabine and cisplatin | DNMT1 | SSL via DNMT1 | 1 | ||||||||
| gemcitabine, oxaliplatin, imatinib | ABL1 | SSL via ABL1 | 1 | ||||||||
| genistein, erlotinib hydrochloride, gemcitabine hydrochloride | CFTR | SSL via CFTR | 1 | ||||||||
| genistein, erlotinib hydrochloride, gemcitabine hydrochloride | ESR2 | SSL via ESR2 | 1 | ||||||||
| imatinib, irinotecan, carboplatin | ABL1 | SSL via ABL1 | 1 | ||||||||
| kras tcr-transduced pbl, aldesleukin, fludarabine, cyclophosphamide | IL2RB | SSL via IL2RB | 1 | ||||||||
| lmb-100, tofacitinib, mesothelin expression | JAK2 | SSL via JAK2 | 1 | ||||||||
| nivolumab, tadalafil, oral vancomycin | PDE5A | SSL via PDE5A | 1 | ||||||||
| paclitaxel, bryostatin 1 | CASP8 | SSL via CASP8 | 1 | ||||||||
| pacritinib, sirolimus, tacrolimus, allogenic hematopoietic cell transplant (allohct) | JAK2 | SSL via JAK2 | 1 | ||||||||
| pd0332991, anastrozole, goserelin, surgery (standard of care), tumor biopsy | GNRHR | SSL via GNRHR | 1 | ||||||||
| pegph20, nab-paclitaxel, gemcitabine, dexamethasone, enoxaparin | F2 | SSL via F2 | 1 | ||||||||
| pembrolizumab, azacitidine | DNMT1 | SSL via DNMT1 | 1 | ||||||||
| pembrolizumab, tadalafil | PDE5A | SSL via PDE5A | 1 | ||||||||
| pep-3-klh conjugate vaccine, daclizumab, temozolomide, placebo, pep-3-klh | IL2RB | SSL via IL2RB | 1 | ||||||||
| ponatinib | ABL1 | SSL via ABL1 | yes | 1 | |||||||
| proflavine | F2 | SSL via F2 | 1 | ||||||||
| proflavine, mobile, augmented high resolution microendoscope | F2 | SSL via F2 | 1 | ||||||||
| propranolol, esophageal variceal ligation | ADRB3 | SSL via ADRB3 | 1 | ||||||||
| propranolol, placebo | ADRB3 | SSL via ADRB3 | 1 | ||||||||
| regorafenib, lomustine | ABL1 | SSL via ABL1 | 1 | ||||||||
| regorafenib, nivolumab, capeox, folfox regimen | ABL1 | SSL via ABL1 | 1 | ||||||||
| regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil | ABL1 | SSL via ABL1 | 1 |